FinnGen study is funded by Business Finland and the pharmaceutical industry partners. The funding allocated for the first three years (FinnGen1: 2017-2020) is approximately 40 M €. The whole budget exceeds 80 M€.

The graph belows shows the FinnGen expenditure distribution for the first three years of the study. The data is based on March 2020 situation / budget forecast. Half of the funding has been used to cover costs related to biobank sample collection and handling. The next largest items of expenditure are data processing & analyses activities (30 % of the budget, mainly personnel costs) and genotyping with ThermoFisher's array (14 % of the budget). In addition, significant investments to IT and data security have been made (6 % of the budget).

Graph showing the expenditure distribution of FinnGen. The largest budget items are listed in the text. In addition, the graph contains the following items: Management, coordination and outreach (6%), Pilot studies (2%) and Meetings and travel (2%).

The total budget exceeds 85 M €. Approximately 20 M € comes from Business Finland and the rest from the international pharmaceutical industry partners: AbbVie, AstraZeneca, Biogen, Boehringer Ingelheim, Celgene/Bristol-Myers Scibb, Genentech (a member of the Roche Group), GSK, Janssen, Maze Therapeutics, MSD/Merck, Novartis, Pfizer and Sanofi.